Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell‐surface antigen‐2 (Trop‐2) – a cell‐surface glycoprotein highly expressed in many epithelial tumors – and delivers the active met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Perrone, Emanuele, Manara, Paola, Lopez, Salvatore, Bellone, Stefania, Bonazzoli, Elena, Manzano, Aranzazu, Zammataro, Luca, Bianchi, Anna, Zeybek, Burak, Buza, Natalia, Tymon‐Rosario, Joan, Altwerger, Gary, Han, Chanhee, Menderes, Gulden, Huang, Gloria S., Ratner, Elena, Silasi, Dan‐Arin, Azodi, Masoud, Hui, Pei, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053235/
https://ncbi.nlm.nih.gov/pubmed/31891442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12627
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados